


- 102 -

What is claimed is:

1. A compound of formula (I):



wherein

each of x and y is, independently of the other, 0 or 1;

R₁ is an organic moiety that can be bound to nitrogen;

X is C=O (especially preferred) or C=S with the proviso that then the dashed line bonding X to N is absent, so that X is bound to the adjacent N via a single bond and with the proviso that then y is 1 and R is hydrogen or an organic moiety that can be bound to nitrogen, or

X is (CR₇), wherein R₇ is hydrogen or an organic or inorganic moiety with the proviso that then the dashed line bonding X to N is a bond, so that X is bound to the adjacent N via a double bond, and with the proviso that then y is zero or y is 1 and then -R is →O; and

each of R₂, R₃, R₄, R₅ and R₆, independently of the others, is an organic moiety or hydrogen or an inorganic moiety, with the proviso that R₃ cannot be unsubstituted phenyl unless R₁ is phenyl substituted with a heterocyclic ring;

or a pharmaceutically acceptable salt thereof.

2. A compound according to Claim 1,

wherein

each of x and y is, independently of the other, 0 or 1;

R₁ is substituted or unsubstituted aryl or heteroaryl, especially phenyl, which is substituted with up to 4 substituents, preferably up to 3 substituents, where the substituents are the same or different and are independently selected from halo, e.g., F or Cl; C₁-C₇ lower alkyl which may be unsubstituted or substituted with halo,

- 103 -

especially methyl, ethyl, propyl or trifluoromethyl; cyano; cyano-lower alkyl, e.g., cyanomethyl, cyanoethyl or cyanopropyl; lower alkoxy; amino; amino-lower alkyl; amino-lower alkoxy; amino-lower alkyl sulfanyl; or thiol-lower alkyl, wherein the amino group can be mono- or di-substituted, e.g., $-(C_1-C_7)_mNR_8R_9$ or $-O-(C_1-C_7)_mNR_8R_9$,

wherein

m is 0 or 1; and

R_8 and R_9 can be the same or different and are independently H; lower alkyl, e.g., methyl, ethyl or propyl; lower cycloalkyl, e.g., cyclopropyl, or

R_8 and R_9 , together with the N atom, form a 3- to 8-membered heterocyclic ring containing 1-4 nitrogen, oxygen or sulfur atoms, e.g., azetidiny, pyrrolidinyl, piperidino, morpholinyl, imidazoliny, imidazoliny-ethyl, piperaziny or lower alkyl-piperaziny; amino-carbonyl-lower alkyl, e.g., $R_8R_9-N-C(O)-CH_2-$, wherein R_8 and R_9 are as defined above; heterocyclyl; heterocyclyl-lower alkyl; heterocyclyl-lower alkoxy; or heterocyclyl-lower alkanesulfanyl, wherein the heterocyclyl is a 3- to 8-membered heterocyclic ring containing 1-4 nitrogen, oxygen or sulfur atoms, e.g., imidazolyl, imidazoliny, pyrrolidinyl, morpholinyl, azetidiny, pyridyl, piperidino, piperidyl, piperaziny or lower alkyl-piperaziny; substituted or unsubstituted amide; amide-lower alkyl, e.g., $-CH_2-CH(NH_2)-C(O)-NH_2$), wherein alkyl may be linear or cyclic, e.g., cyclopropylene; and the alkyl in any of the substituents above may optionally be substituted with $-NR_8R_9$, wherein R_8 and R_9 are as defined above;

X is C=O or C=S, with the proviso that then the dashed line bonding X to N is absent, so that X is bound to the adjacent N via a single bond and with the proviso that then y is 1 and R is hydrogen or an organic moiety that can be bound to nitrogen, or

X is (CR_7) , wherein R_7 is hydrogen or an organic moiety, such as C_1-C_7 lower alkyl; amino; or amino alkyl, wherein the alkyl may be unsubstituted or substituted with halo, e.g., methyl, ethyl, propyl or trifluoromethyl; lower alkoxy, e.g., methoxy; or cycloalkyl, e.g., cyclopropyl; with the proviso that then the dashed line bonding X to N is a bond, so that X is bound to the adjacent N via a double bond; and with the proviso that then y is zero, or y is 1 and then $-R$ is $\rightarrow O$;

R_2 is hydrogen;

- 104 -

R_3 is unsubstituted or substituted C_5 - C_{14} heterocyclyl, e.g., thienyl, benzo[1,3]dioxolo, indolyl, benzofuranyl or pyridiyl; unsubstituted or substituted C_5 - C_{14} aryl, e.g., phenyl or phenyl substituted with up to 4 substituents, preferably up to 3 substituents, which are the same or different and are selected from halo, e.g., Cl or F; hydroxy; C_1 - C_4 lower alkoxy, e.g., methoxy; lower alkyl, e.g., methyl; or $-(C_1-C_4)_mNR_8R_9$, wherein

m is 0 or 1; and

R_8 and R_9 , are as defined above, e.g., piperazinyl, methylpiperazinyl, morpholinyl or pyrrolidinyl;

R_4 is hydrogen or halo, e.g., fluoro or chloro;

R_5 is hydrogen; and

R_6 is hydrogen, amino, amino alkyl or alkylamido, e.g., methylamido $-NHC(O)-CH_3$), with the proviso that R_3 cannot be unsubstituted phenyl unless R_1 is phenyl substituted with an heterocyclic ring;

or a pharmaceutically acceptable salt thereof.

3. A compound according to Claim 1,

wherein

each of x and y is, independently of the other, 0 or 1;

R_1 is substituted or unsubstituted phenyl where the phenyl is substituted with up to 4 substituents, preferably up to 3 substituents, where the substituents are the same or different and are independently selected from halo, e.g., F or Cl; C_1 - C_7 lower alkyl, which may be unsubstituted or substituted with halo, especially methyl, ethyl, propyl or trifluoromethyl; cyano; cyano-lower alkyl, e.g., cyanomethyl, cyanoethyl or cyanopropyl; amino; amino-lower alkyl, wherein the amino group can be mono- or di-substituted, e.g., $-(C_1-C_7)_mNR_8R_9$ or $-O-(C_1-C_7)_mNR_8R_9$,

wherein

m is 0 or 1; and

R_8 and R_9 can be the same or different and are independently H; lower alkyl, e.g., methyl, ethyl or propyl; lower cycloalkyl, e.g., cyclopropyl, or

R_8 and R_9 , together with the N atom, form a 3- to 8-membered heterocyclic ring containing 1-4 nitrogen, oxygen or sulfur atoms, e.g., imidazoliny, imidazoliny-ethyl, piperazinyl or lower alkyl-piperazinyl; amino-carbonyl-lower alkyl, e.g.,

- 105 -

$R_8R_9-N-C(O)-CH_2-$, wherein R_8 and R_9 are as defined above; heterocyclyl; heterocyclyl-lower alkyl; heterocyclyl-lower alkoxy; or heterocyclyl-lower alkanesulfanyl, wherein the heterocyclyl is a 3- to 8-membered heterocyclic ring containing 1-4 nitrogen, oxygen or sulfur atoms, e.g., imidazoliny, imidazoliny, imidazoliny-ethyl, piperaziny or lower alkyl-piperaziny; substituted or unsubstituted amide; amide-lower alkyl, e.g., $-CH_2-CH(NH_2)-C(O)-NH_2$, wherein alkyl may be linear or cyclic, e.g., cyclopropylene; and the alkyl in any of the substituents above may optionally be substituted with $-NR_8R_9$, wherein R_8 and R_9 are as defined above;

X is (CR_7) , wherein R_7 is hydrogen; lower alkyl, e.g., methyl or ethyl; amino; or amino alkyl, with the proviso that then the dashed line bonding X to N is a bond, so that X is bound to the adjacent N via a double bond, and with the proviso that then y is zero, or y is 1 and then $-R$ is $\rightarrow O$;

R_2 is hydrogen;

R_3 is unsubstituted or substituted C_5-C_{14} heterocyclyl, e.g., thienyl, benzo[1,3]dioxolo, indolyl, benzofuranyl or pyridyl; unsubstituted or substituted C_5-C_{14} aryl, e.g., phenyl or phenyl substituted with up to 4 substituents, preferably up to 3 substituents, which are the same or different and are selected from halo, e.g., Cl or F; hydroxy; C_1-C_4 lower alkoxy, e.g., methoxy; lower alkyl, e.g., methyl; or $-(C_1-C_4)_mNR_8R_9$,

wherein

m is 0 or 1; and

R_8 and R_9 are as defined above, e.g., piperaziny, methylpiperaziny, morpholiny or pyrrolidiny;

R_4 is hydrogen or halo, (e.g. fluoro or chloro);

R_5 is hydrogen; and

R_6 is hydrogen, with the proviso that R_3 cannot be unsubstituted phenyl unless R_1 is phenyl substituted with an heterocyclic ring;

or a pharmaceutically acceptable salt thereof.

4. A pharmaceutical composition comprising a compound of formula (I), according to any of Claims 1-3, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.


- 106 -

5. A compound of the formula (I), according to any one of Claims 1-3, for use in the treatment of the animal or human body, especially in the treatment of a protein kinase dependent disease.
6. A compound according to Claim 5, wherein the protein kinase dependent disease is preferably one depending on PKB, ALK, S6K1 or RET and (especially aberrantly highly-expressed or activated) PKB, ALK, S6K1 or RET-dependent disease or disease dependent on the activation of the PKB, ALK, S6K1 or RET pathways, or a disease dependent on any two or more of the kinases just mentioned.
7. Use of a compound of formula (I), according to any one of Claims 1-3, or a pharmaceutically acceptable salt thereof, in the treatment of a protein kinase dependent disease.
8. Use of a compound of formula (I), according to any one of Claims 1-3, or a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical composition for use in the treatment of a protein kinase dependent disease.
9. The use according to Claims 7 and 8, wherein the protein kinase dependent disease is preferably one depending on PKB, ALK, S6K1 or RET and (especially aberrantly highly-expressed or activated) PKB, ALK, S6K1 or RET-dependent disease or disease dependent on the activation of the PKB, ALK, S6K1 or RET pathways, or a disease dependent on any two or more of the kinases just mentioned.
10. A method of treatment of a disease that responds to inhibition of a protein kinase, which comprises administering a prophylactically or especially therapeutically effective amount of a compound of formula (I) according to any one of Claims 1-3, or a pharmaceutically acceptable salt thereof, to a warm-blooded animal, e.g., a human, in need of such treatment.
11. A method according to Claim 10, wherein the disease to be treated is a proliferative disease, preferably a benign or especially malignant tumor, more preferably carcinoma of the brain, kidney, liver, adrenal gland, bladder, breast, stomach, gastric tumors, ovaries, colon, rectum, prostate, pancreas, lung, vagina, thyroid, sarcoma, glioblastomas, multiple myeloma, gastrointestinal cancer, colon carcinoma, colorectal adenoma, tumor of the neck and head,

- 107 -

an epidermal hyperproliferation, psoriasis, prostate hyperplasia, a neoplasia, especially of epithelial character, mammary carcinoma, leukemia, metabolic diseases, type II diabetes, obesity, hyperlipidemia and atherosclerosis.

12. A compound according to formula (I), for use in the treatment of a protein kinase dependent disease, especially one depending on ALK, S6K1 or RET and (especially aberrantly highly-expressed or activated) ALK, S6K1 or RET-dependent disease or disease dependent on the activation of the ALK, S6K1 or RET pathways or disease comprising administering a compound according to formula (I)



wherein

each of x and y is, independently of the other, 0 or 1;

R₁ is an organic moiety that can be bound to nitrogen;

X is C=O, especially preferred or C=S, with the proviso that then the dashed line bonding X to N is absent, so that X is bound to the adjacent N via a single bond and with the proviso that then y is 1 and R is hydrogen or an organic moiety that can be bound to nitrogen, or

X is (CR₇), wherein R₇ is hydrogen or an organic or inorganic moiety with the proviso that then the dashed line bonding X to N is a bond, so that X is bound to the adjacent N via a double bond, and with the proviso that then y is zero or y is 1 and then -R is →O; and

each of R₂, R₃, R₄, R₅ and R₆, independently of the others, is an organic moiety or hydrogen or an inorganic moiety;

or a pharmaceutically acceptable salt thereof.

- 108 -

13. A compound according to Claim 12, comprising a the compound of the formula (I), or a pharmaceutically acceptable salt thereof,

wherein

each of x and y is, independently of the other, 0 or 1;

R₁ is phenyl or phenyl-lower alkyl, each of which, in the phenyl moiety, is unsubstituted or substituted by up to three moieties independently selected from halogen, especially fluoro, chloro, bromo or iodo; lower alkyl, especially methyl or ethyl; halo-lower alkyl, especially trifluoromethyl; hydroxy; lower alkoxy, especially methoxy; C₆-C₁₄aryl, especially phenyl; hydroxy-lower alkyl, especially 2-hydroxyethyl or hydroxymethyl; amino; amino-lower alkyl, especially aminomethyl or 2-aminoethyl; amidino; *N*-hydroxy-amidino; amidino-lower alkyl, such as 2-amidinoethyl; *N*-hydroxyamidino-lower alkyl, especially *N*-hydroxy-amidino-methyl or -2-ethyl; cyano-lower alkyl, especially cyanomethyl; and cyano or is C₃-C₈cycloalkyl, especially cyclohexyl; or hydroxyC₃-C₈cycloalkyl, especially hydroxy-cyclohexyl;

X is C=O or C=S, with the proviso that then the dashed line bonding X to N is absent, so that X is bound to the adjacent N via a single bond, and with the proviso that then y is 1 and R is hydrogen; lower alkyl, especially methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, 2,2-dimethylpropyl or 2-ethyl-*n*-butyl; mono- or di-hydroxy-lower alkyl, especially 2,3-dihydroxy-propyl or 3-hydroxy-2,2-dimethylpropyl; C₆-C₁₄aryl, which is unsubstituted or substituted by 1-3 substituents selected from lower alkyl, especially methyl or ethyl; halo-lower alkyl, especially trifluoromethyl; halogen, especially chloro; amino; lower alkanoylamino; lower alkoxy, especially methoxy and nitro; C₃-C₈cycloalkyl, especially cyclopropylmethyl or cyclohexylmethyl; or furanyl-lower alkyl, especially 3-furanyl-methyl, or

X is (CR₇), wherein R₇ is hydrogen or an organic or inorganic moiety that can be bound to nitrogen with the proviso that then the dashed line bonding X to N is a bond, so that X is bound to the adjacent N via a double bond, and with the proviso that then y is zero, or y is 1 and then -R is →O;

R₂ is hydrogen;

R₃ is hydrogen; lower alkyl, especially ethyl; halo, especially fluoro, chloro or bromo; lower alkoxy, especially methoxy; or unsubstituted or substituted C₆-C₁₄aryl, especially phenyl, hydroxyphenyl or methoxyphenyl;

R₄ is hydrogen or halo, especially chloro;

- 109 -

R₅ is hydrogen or lower alkoxy, especially *n*-lower hexyloxy; and

R₆ is hydrogen, halo, especially chloro; C₆-C₁₄aryl, especially phenyl; C₃-C₈cycloalkyl, especially cyclopropyl; amino; lower alkyl-amino, especially methylamino or *n*-butylamino; hydroxy-lower alkylamino, especially 2-hydroxyethyl-amino; or C₆-C₁₄arylcarbonylamino, especially benzoylamino.

14. Use of a compound of formula (I), according to Claim 12 or 13, for use in the preparation of a pharmaceutical composition for the treatment of a protein kinase dependent disease, especially one depending on ALK, S6K1 or RET and (especially aberrantly highly-expressed or activated) ALK, S6K1 or RET-dependent disease or disease dependent on the activation of the ALK, S6K1 or RET pathways or disease.

15. A compound according to Claim 1, selected from the group consisting of:

[4-(8-Benzo[1,3]dioxol-5-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;
[4-(8-Thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;
[4-(8-Benzofuran-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;
2-[4-(8-Benzo[1,3]dioxol-5-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;
2-[4-(8-Thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;
2-[4-(8-Benzofuran-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;
[3-Chloro-4-(8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;
(4-Amino-3-chloro-phenyl)-acetonitrile;
{3-Chloro-4-[8-(1*H*-indol-5-yl)-imidazo[4,5-*c*]quinolin-1-yl]-phenyl}-acetonitrile;
[3-Chloro-4-(8-thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;
2-[3-Chloro-4-(8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;
2-{3-Chloro-4-[8-(1*H*-indol-5-yl)-imidazo[4,5-*c*]quinolin-1-yl]-phenyl}-ethylamine;
2-[3-Chloro-4-(8-thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;
[2-Fluoro-4-(8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;
[4-(8-Benzofuran-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-2-fluoro-phenyl]-acetonitrile;
{2-Fluoro-4-[8-(1*H*-indol-5-yl)-imidazo[4,5-*c*]quinolin-1-yl]-phenyl}-acetonitrile;
2-[2-Fluoro-4-(8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;
2-[4-(8-Benzofuran-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-2-fluoro-phenyl]-ethylamine;

- 110 -

2-{2-Fluoro-4-[8-(1*H*-indol-5-yl)-imidazo[4,5-*c*]quinolin-1-yl]-phenyl}-ethylamine;
[3-Methyl-4-(8-thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;
{4-[8-(1*H*-Indol-5-yl)-imidazo[4,5-*c*]quinolin-1-yl]-3-methyl-phenyl}-acetonitrile;
2-[3-Methyl-4-(8-thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;
2-{4-[8-(1*H*-Indol-5-yl)-imidazo[4,5-*c*]quinolin-1-yl]-3-methyl-phenyl}-ethylamine;
(*R*)-2-Amino-3-[4-(8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propionamide;
(*R*)-2-Amino-3-[4-(8-benzo[*b*]thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propionamide;
[3,5-Dichloro-4-(8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;
[3,5-Dichloro-4-(8-thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;
2-[3,5-Dichloro-4-(8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;
2-[3,5-Dichloro-4-(8-thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;
{4-[8-(4-Hydroxy-phenyl)-imidazo[4,5-*c*]quinolin-1-yl]-3-trifluoromethyl-phenyl}-acetonitrile;
4-{1-[4-(2-Amino-ethyl)-2-trifluoromethyl-phenyl]-1*H*-imidazo[4,5-*c*]quinolin-8-yl}-phenol;
3-[4-(8-Benzo[1,3]dioxol-5-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propionitrile;
3-[4-(8-Thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propionitrile;
3-[4-(8-Benzo[*b*]thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propionitrile;
3-[4-(8-Thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propionitrile;
3-[4-(8-Benzofuran-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propionitrile;
3-[4-(8-Benzo[1,3]dioxol-5-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propylamine;
3-[4-(8-Thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propylamine;
3-[4-(8-Benzo[*b*]thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propylamine;
3-[4-(8-Thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propylamine;
3-[4-(8-Benzofuran-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propylamine;
3-[4-(8-Benzo[1,3]dioxol-5-yl-imidazo[4,5-*c*]quinolin-1-yl)-3-chloro-phenyl]-propionitrile;
3-[3-Chloro-4-(8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propionitrile;
3-[3-Chloro-4-(8-thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propionitrile;
3-{3-Chloro-4-[8-(1*H*-indol-5-yl)-imidazo[4,5-*c*]quinolin-1-yl]-phenyl}-propionitrile;
3-[4-(8-Benzo[1,3]dioxol-5-yl-imidazo[4,5-*c*]quinolin-1-yl)-3-chloro-phenyl]-propylamine;
3-[3-Chloro-4-(8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propylamine;
3-[3-Chloro-4-(8-thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propylamine;

- 111 -

3-{3-Chloro-4-[8-(1*H*-indol-5-yl)-imidazo[4,5-*c*]quinolin-1-yl]-phenyl}-propylamine;
8-Benzo[1,3]dioxol-5-yl-1-{4-[2-(4,5-dihydro-1*H*-imidazol-2-yl)-ethyl]-phenyl}-1*H*-imidazo[4,5-*c*]quinoline;
[3-Chloro-4-(2-methyl-8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;
[3-Chloro-4-(2-methyl-8-thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;
2-[3-Chloro-4-(2-methyl-8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;
2-[3-Chloro-4-(2-methyl-8-thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;
[4-(8-Benzo[1,3]dioxol-5-yl-7-fluoro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;
[4-(7-Fluoro-8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;
[4-(7-Fluoro-8-thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;
[4-(8-Benzofuran-2-yl-7-fluoro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;
{4-[7-Fluoro-8-(1*H*-indol-5-yl)-imidazo[4,5-*c*]quinolin-1-yl]-phenyl}-acetonitrile;
[4-(8-Benzo[*b*]thiophen-2-yl-7-fluoro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;
2-[4-(8-Benzo[1,3]dioxol-5-yl-7-fluoro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;
2-[4-(7-Fluoro-8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;
2-[4-(7-Fluoro-8-thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;
2-[4-(8-Benzofuran-2-yl-7-fluoro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;
2-{4-[7-Fluoro-8-(1*H*-indol-5-yl)-imidazo[4,5-*c*]quinolin-1-yl]-phenyl}-ethylamine;
2-[4-(8-Benzo[*b*]thiophen-2-yl-7-fluoro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;
3-[4-(8-Benzo[1,3]dioxol-5-yl-7-fluoro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propionitrile;
3-[4-(7-Fluoro-8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propionitrile;
3-[4-(7-Fluoro-8-thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propionitrile;
3-[4-(8-Benzofuran-2-yl-7-fluoro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propionitrile;
3-[4-(8-Benzo[*b*]thiophen-2-yl-7-fluoro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propionitrile;
3-{4-[7-Fluoro-8-(1*H*-indol-5-yl)-imidazo[4,5-*c*]quinolin-1-yl]-phenyl}-propionitrile;
3-[4-(8-Benzo[1,3]dioxol-5-yl-7-fluoro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propylamine;
3-[4-(7-Fluoro-8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propylamine;
3-[4-(7-Fluoro-8-thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propylamine;
3-[4-(8-Benzofuran-2-yl-7-fluoro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propylamine;
3-[4-(8-Benzo[*b*]thiophen-2-yl-7-fluoro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propylamine;

- 112 -

3-{4-[7-Fluoro-8-(1*H*-indol-5-yl)-imidazo[4,5-*c*]quinolin-1-yl]-phenyl}-propylamine;
[3-Chloro-4-(7-fluoro-8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;
[3-Chloro-4-(7-fluoro-8-thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;
{3-Chloro-4-[7-fluoro-8-(1*H*-indol-5-yl)-imidazo[4,5-*c*]quinolin-1-yl]-phenyl}-acetonitrile;
2-[3-Chloro-4-(7-fluoro-8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;
2-[3-Chloro-4-(7-fluoro-8-thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;
2-{3-Chloro-4-[7-fluoro-8-(1*H*-indol-5-yl)-imidazo[4,5-*c*]quinolin-1-yl]-phenyl}-ethylamine;
[4-(7-Chloro-8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;
[4-(7-Chloro-8-thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;
[4-(8-Benzofuran-2-yl-7-chloro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;
{4-[7-Chloro-8-(1*H*-indol-5-yl)-imidazo[4,5-*c*]quinolin-1-yl]-phenyl}-acetonitrile;
[4-(8-Benzo[*b*]thiophen-2-yl-7-chloro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;
2-[4-(7-Chloro-8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;
2-[4-(7-Chloro-8-thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;
2-[4-(8-Benzofuran-2-yl-7-chloro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;
2-{4-[7-Chloro-8-(1*H*-indol-5-yl)-imidazo[4,5-*c*]quinolin-1-yl]-phenyl}-ethylamine;
2-[4-(8-Benzo[*b*]thiophen-2-yl-7-chloro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;
3-[4-(8-Benzo[1,3]dioxol-5-yl-7-chloro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propionitrile;
3-[4-(7-Chloro-8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propionitrile;
3-[4-(8-Benzofuran-2-yl-7-chloro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propionitrile;
3-{4-[7-Chloro-8-(1*H*-indol-5-yl)-imidazo[4,5-*c*]quinolin-1-yl]-phenyl}-propionitrile;
3-[4-(8-Benzo[*b*]thiophen-2-yl-7-chloro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propionitrile;
3-[4-(8-Benzo[1,3]dioxol-5-yl-7-chloro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propylamine;
3-[4-(7-Chloro-8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propylamine;
3-[4-(8-Benzofuran-2-yl-7-chloro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propylamine;
3-{4-[7-Chloro-8-(1*H*-indol-5-yl)-imidazo[4,5-*c*]quinolin-1-yl]-phenyl}-propylamine;
3-[4-(8-Benzo[*b*]thiophen-2-yl-7-chloro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propylamine;
[3-Chloro-4-(7-chloro-8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;
[3-Chloro-4-(7-chloro-8-thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;
2-[3-Chloro-4-(7-chloro-8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;

- 113 -

2-[3-Chloro-4-(7-chloro-8-thiophen-3-yl-imidazo[4,5-c]quinolin-1-yl)-phenyl]-ethylamine;
3-[3-Chloro-4-(7-chloro-8-thiophen-2-yl-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile;
3-[3-Chloro-4-(7-chloro-8-thiophen-3-yl-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile;
3-{3-Chloro-4-[7-chloro-8-(1*H*-indol-5-yl)-imidazo[4,5-c]quinolin-1-yl]-phenyl}-propionitrile;
3-[3-Chloro-4-(7-chloro-8-thiophen-2-yl-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propylamine;
3-[3-Chloro-4-(7-chloro-8-thiophen-3-yl-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propylamine;
3-{3-Chloro-4-[7-chloro-8-(1*H*-indol-5-yl)-imidazo[4,5-c]quinolin-1-yl]-phenyl}-propylamine;
3-[4-(2-Amino-7-chloro-8-thiophen-3-yl-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile;
3-[4-(2-Amino-8-bromo-7-chloro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile;
3-[4-(3-Amino-6-bromo-7-chloro-quinolin-4-ylamino)-phenyl]-propionitrile;
3-[4-(2-Amino-8-benzofuran-2-yl-7-chloro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile;
1-[4-(3-Amino-propyl)-phenyl]-7-chloro-8-thiophen-3-yl-1*H*-imidazo[4,5-c]quinolin-2-ylamine;
1-[4-(3-Amino-propyl)-phenyl]-8-benzofuran-2-yl-7-chloro-1*H*-imidazo[4,5-c]quinolin-2-ylamine;
8-(2,4-Dimethoxy-phenyl)-1-(2-fluoro-phenyl)-1*H*-imidazo[4,5-c]quinoline;
8-(2,5-Dimethoxy-phenyl)-1-(2-fluoro-phenyl)-1*H*-imidazo[4,5-c]quinoline;
8-(3,4-Dimethoxy-phenyl)-1-(2-fluoro-phenyl)-1*H*-imidazo[4,5-c]quinoline;
1-(2-Fluoro-phenyl)-8-(3,4,5-trimethoxy-phenyl)-1*H*-imidazo[4,5-c]quinoline;
8-(2,3-Dimethoxy-phenyl)-1-(2-fluoro-phenyl)-1*H*-imidazo[4,5-c]quinoline;
1-(2-Fluoro-phenyl)-8-(2,3,4-trimethoxy-phenyl)-1*H*-imidazo[4,5-c]quinoline;
1-(2-Fluoro-phenyl)-8-pyridin-4-yl-1*H*-imidazo[4,5-c]quinoline;
1-(2-Fluoro-phenyl)-8-pyridin-3-yl-1*H*-imidazo[4,5-c]quinoline;
1-(2-Fluoro-phenyl)-8-(3-methoxy-phenyl)-1*H*-imidazo[4,5-c]quinoline;
{3-[1-(2-Fluoro-phenyl)-1*H*-imidazo[4,5-c]quinolin-8-yl]-benzyl}-dimethyl-amine;
1-(2-Fluoro-phenyl)-8-[3-(4-methyl-piperazin-1-ylmethyl)-phenyl]-1*H*-imidazo[4,5-c]quinoline;
1-(2-Fluoro-phenyl)-8-(3-morpholin-4-ylmethyl-phenyl)-1*H*-imidazo[4,5-c]quinoline;
1-(2-Fluoro-phenyl)-8-(3-piperazin-1-ylmethyl-phenyl)-1*H*-imidazo[4,5-c]quinoline;
1-(2-Fluoro-phenyl)-8-(3-pyrrolidin-1-ylmethyl-phenyl)-1*H*-imidazo[4,5-c]quinoline;
1-Phenyl-8-(3-piperazin-1-yl-phenyl)-1*H*-imidazo[4,5-c]quinoline;
8-(3-Fluoro-phenyl)-1-phenyl-1*H*-imidazo[4,5-c]quinoline;

- 114 -

8-[3-(4-Methyl-piperazin-1-yl)-phenyl]-1-phenyl-1*H*-imidazo[4,5-*c*]quinoline;
4-{1-[4-(4-Methyl-piperazin-1-yl)-phenyl]-1*H*-imidazo[4,5-*c*]quinolin-8-yl}-phenol;
1-[4-(4-Methyl-piperazin-1-yl)-phenyl]-8-phenyl-1*H*-imidazo[4,5-*c*]quinoline; and
[4-(8-Pyridin-4-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile.